Overview

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Status:
Completed
Trial end date:
2015-03-24
Target enrollment:
Participant gender:
Summary
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
Phase:
Phase 4
Details
Lead Sponsor:
ViiV Healthcare
Collaborator:
Pfizer
Treatments:
Anti-Retroviral Agents
Maraviroc